Shattuck Labs, Inc. (STTK): History, Ownership, Mission, How It Works & Makes Money

Ever heard of Shattuck Labs, Inc. (STTK) and wondered what they're all about? This clinical-stage biotechnology company, founded in 2016, is pioneering the development of bi-functional fusion proteins for treating cancer and autoimmune diseases, with a focus on novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors. With $5.72 million in revenue for 2024, a 245.26% increase from the previous year, and a recent presentation of preclinical data for their lead product candidate SL-325 at the ECCO 2025, isn't it time to delve deeper into their history, ownership, mission, and how they operate?

Shattuck Labs is focused on developing treatments for inflammatory and immune-mediated diseases. Their lead product candidate, SL-325, is designed to inhibit the interaction between death receptor 3 (DR3) and its ligand, TL1A. The company is also developing SL-425, a half-life extended version of SL-325. As of December 31, 2024, Shattuck Labs had approximately $73.0 million in cash, expected to fund operations into 2027.

Shattuck Labs, Inc. (STTK) History

Shattuck Labs, Inc. Founding Timeline

Year established

Shattuck Labs, Inc. was founded in 2016.

Original location

The company is headquartered in Austin, Texas.

Founding team members

Shattuck Labs was co-founded by:

• Gregory L. Verdine, Ph.D.
• Taylor Schreiber, M.D., Ph.D.

Initial capital/funding

In November 2018, Shattuck Labs completed a Series A financing round, securing $38 million. This funding was led by Redmile Group and included participation from EcoR1 Capital, Janus Henderson Investors, and Hatteras Venture Partners.

Shattuck Labs, Inc. Evolution Milestones

Shattuck Labs, Inc. Transformative Moments

• Strategic Platform Development: Shattuck’s focus on developing the ARC platform and ONK linchpin platform marked a pivotal shift towards creating a novel class of therapeutics.
• Key Partnerships and Collaborations: Collaborations, such as the one with Takeda, have expanded the company's research capabilities and potential therapeutic applications.
• Financial Milestones: The successful IPO in 2020 provided substantial capital to further advance clinical programs.
• Clinical Data Readouts: Positive clinical data, such as the Phase 1B results for SL-172154, have validated the company's scientific approach and enhanced its market position.

To gain further insights into the company's goals and guiding principles, explore: Mission Statement, Vision, & Core Values of Shattuck Labs, Inc. (STTK).

Shattuck Labs, Inc. (STTK) Ownership Structure

Understanding the ownership structure of Shattuck Labs, Inc. (STTK) provides valuable insights into its governance and strategic direction. The company's ownership is distributed among various shareholders, including institutional investors, individual shareholders, and potentially company insiders.

Shattuck Labs, Inc. Current Status

Shattuck Labs, Inc. is a public company, trading on the Nasdaq Global Market under the ticker symbol STTK.

Shattuck Labs, Inc. Ownership Breakdown

Detailed information on Shattuck Labs' ownership can be found in their SEC filings, such as 13F filings, which disclose the holdings of institutional investors. As of the latest available data, the ownership breakdown is as follows:

Shattuck Labs, Inc. Leadership

The leadership team at Shattuck Labs, Inc. is responsible for guiding the company's strategic initiatives and overseeing its operations. Key members of the leadership team include:

• Dr. Taylor Schreiber: Chairman of the Board, President, and Chief Executive Officer
• Andrew J. Maine, MBA: Chief Financial Officer
• Lori Rafield, J.D.: Chief Legal Officer
• Dr. Joson Marakovsky: Chief Scientific Officer
• Gregory Berk, MD: Chief Medical Officer

More insights into Shattuck Labs, Inc. can be found here: Exploring Shattuck Labs, Inc. (STTK) Investor Profile: Who’s Buying and Why?

Shattuck Labs, Inc. (STTK) Mission and Values

Shattuck Labs is dedicated to pioneering innovative cancer treatments by developing next-generation immunotherapies. Their mission is rooted in translating scientific breakthroughs into clinical benefits for patients.

Shattuck Labs' Core Purpose

Official mission statement

Shattuck Labs' mission statement is to develop transformative medicines for patients with cancer and autoimmune disease by applying its proprietary Agonist Redirected Checkpoint (ARC®) platform to create novel immunotherapies.

• Focuses on developing transformative medicines.
• Targets cancer and autoimmune diseases.
• Utilizes the ARC® platform to create novel immunotherapies.

Vision statement

While a specific, formal vision statement is not publicly available, Shattuck Labs' vision can be inferred from their activities and goals: to become a leader in the development of innovative immunotherapies, significantly improving outcomes for patients with cancer and autoimmune disorders.

• Aims to lead in innovative immunotherapy development.
• Seeks to improve outcomes for cancer and autoimmune disease patients.
• Strives to translate scientific advancements into clinical benefits.

Company slogan/tagline

Shattuck Labs does not have a widely publicized official slogan or tagline. However, considering their focus and mission, an unofficial tagline could be: 'Redirecting Immunity, Redefining Treatment.'

• No official tagline is publicly available.
• Dedication to redirecting immunity.
• Focus on redefining cancer and autoimmune disease treatment.

To gain more insights into Shattuck Labs, Inc., explore this comprehensive investor profile: Exploring Shattuck Labs, Inc. (STTK) Investor Profile: Who’s Buying and Why?

Shattuck Labs, Inc. (STTK) How It Works

Shattuck Labs, Inc. operates as a clinical-stage biotechnology company, pioneering the development of novel cancer therapies by leveraging its proprietary Agonist Redirected Checkpoint (ARC®) platform to create bifunctional fusion proteins. These proteins are designed to simultaneously block checkpoint molecules and activate costimulatory receptors, aiming to enhance the immune system's ability to fight cancer.

Shattuck Labs' Product/Service Portfolio

Shattuck Labs' Operational Framework

Shattuck Labs focuses on the research and development of its ARC® platform-derived therapies. Key operational aspects include:

• Drug Discovery and Development: Identifying and validating novel ARC® molecules, conducting preclinical studies to assess safety and efficacy, and advancing promising candidates into clinical trials.
• Clinical Trials: Executing Phase 1 and Phase 2 clinical trials to evaluate the safety, tolerability, and efficacy of its lead drug candidates in various cancer types.
• Manufacturing: Establishing partnerships with contract manufacturing organizations (CMOs) to produce clinical-grade drug supplies.
• Partnerships and Collaborations: Engaging in strategic collaborations with other pharmaceutical companies and academic institutions to expand its research capabilities and accelerate drug development.

Shattuck Labs' Strategic Advantages

Shattuck Labs possesses several strategic advantages that contribute to its potential for success in the competitive biotechnology landscape:

• Novel Technology Platform: The ARC® platform represents a unique approach to cancer immunotherapy, potentially offering improved efficacy and safety compared to traditional checkpoint inhibitors.
• Bifunctional Design: The bifunctional nature of ARC® molecules allows for simultaneous targeting of two distinct pathways, potentially leading to synergistic anti-tumor effects.
• Strong Intellectual Property: Shattuck Labs has a growing patent portfolio protecting its ARC® platform and drug candidates.

To gain more insights into the company's financial stability, you might find this resource helpful: Breaking Down Shattuck Labs, Inc. (STTK) Financial Health: Key Insights for Investors.

Shattuck Labs, Inc. (STTK) How It Makes Money

Shattuck Labs, Inc. operates as a clinical-stage biotechnology company, primarily focusing on the discovery and development of cancer therapeutics. The company generates revenue through strategic collaborations and licensing agreements related to its proprietary Agonist Redirected Checkpoint (ARC®) platform.

Shattuck Labs, Inc. (STTK) Revenue Breakdown

As a clinical-stage company, Shattuck Labs' revenue streams are primarily tied to its collaborative agreements and licensing activities. While specific percentages may fluctuate, the following table provides a general overview based on available information:

Shattuck Labs, Inc. (STTK) Business Economics

Shattuck Labs' business economics are characterized by substantial investment in research and development, typical for a biotechnology firm. Key aspects include:

• R&D Investment: A significant portion of operating expenses is allocated to advancing its ARC® platform and pipeline programs.
• Partnerships: Strategic alliances with larger pharmaceutical companies provide crucial funding and validation for its technology.
• Clinical Trial Expenses: Costs associated with clinical trials represent a major expenditure, influencing the company's financial outlook.

Shattuck Labs, Inc. (STTK) Financial Performance

Shattuck Labs' financial performance reflects its status as a development-stage company. Key points to consider include:

• Revenue Generation: Revenue is primarily project-based, tied to milestones achieved in collaboration agreements.
• Operating Expenses: High R&D costs and administrative expenses result in operating losses.
• Cash Runway: Monitoring cash reserves and burn rate is crucial to assess the company's ability to fund ongoing operations and research activities.

To gain more insights into the company's investor profile, check out this link: Exploring Shattuck Labs, Inc. (STTK) Investor Profile: Who’s Buying and Why?

Shattuck Labs, Inc. (STTK) Market Position & Future Outlook

Shattuck Labs is strategically positioned to capitalize on the growing demand for innovative cancer therapies, particularly through its proprietary Agonist Redirected Checkpoint (ARC) platform. While the company faces competition, its unique approach to immunotherapy and strategic partnerships offer a promising future outlook.

Competitive Landscape

Opportunities & Challenges

Industry Position

Shattuck Labs is a clinical-stage biotechnology company focused on developing innovative cancer therapies, particularly those leveraging its Agonist Redirected Checkpoint (ARC) platform. Its standing can be further understood by:

• Focus on Immunotherapy: Shattuck Labs operates within the rapidly growing immunotherapy market, which seeks to harness the body's own immune system to fight cancer.
• Novel Technology: The ARC platform represents a novel approach to immunotherapy, potentially offering advantages over existing checkpoint inhibitors and other immunotherapeutic modalities.
• Clinical Development: The company's product candidates are in various stages of clinical development, with the potential to address unmet needs in specific cancer types.

Learn more about STTK investors: Exploring Shattuck Labs, Inc. (STTK) Investor Profile: Who’s Buying and Why?